Hundreds of children in England prescribed weight-loss jabs, figures show

A recent investigation has uncovered that hundreds of children in England, some as young as 12, are being prescribed weight-loss medications known as GLP-1s. These medications, initially developed for type 2 diabetes, have gained popularity as a weight-loss aid. According to data from the NHS Business Services Authority, there were 419 prescriptions issued to children under 18 in the financial year 2025-26, with 10 of those given to children under 12.

In the first quarter of 2025 alone, 341 prescriptions were issued to children, including 15 under the age of 12. The figures do not include those prescribed via private means, in hospitals, or prisons, likely resulting in an underestimate. Experts stress the importance of specialist supervision and long-term monitoring for these medications, as their effects can be significant but not without risks.

Childhood obesity rates have been on the rise, with 10.7% of children in reception year (ages 4-5) and 22.8% in year 6 (ages 10-11) classified as obese. The NHS has been piloting clinics to address severe obesity in children aged 2-16, with nearly 6,500 children referred since 2021. However, GLP-1 use in children has sparked debate, with some guidelines recommending against their use before age 10.

Nevertheless, recent trial data suggests GLP-1s can be effective for young children with severe obesity, often in conjunction with other medical conditions. Health experts emphasize that these medications are not a cure-all, but rather a tool for children with significant health complications, helping them regain control over their lives and potentially extending their lifespan.